Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis.

An amendment to this paper has been published and can be accessed via the original article.

Correction to: Arthritis Research & Therapy (2020) 22: 115

https://doi.org/10.1186/s13075-020-02199-8

Following publication of the original article [1], the authors identified errors in Fig. 1. The legends in Fig. 1c and d refer to placebo, baricitinib 4-mg and adalimumab treatment groups; the legends should refer to placebo, baricitinib 2-mg, and baricitinib 4-mg and the reference to these two studies in the figure caption are reversed. Additionally, the total number of interruptions for baricitinib 4-mg in RA-BEAM (Fig. 1b) has been corrected from 82 to 62 and the title for RA-BEAM has been corrected from 0-52 weeks to 0-24 weeks; labels have been corrected for MTX (8–14 days) in RA-BEGIN from 28 to 29 and for placebo (15–21 days) in RA-BUILD from 17 to 16.

Fig. 1

Duration of interruptions in the phase 3 studies RA-BEGIN (a), RA-BEAM (b), RA-BEACON (c), and RA-BUILD (d)a,b. aInterruptions are based on daily tablet baricitinib study drug, including in non-baricitinib groups, which represent interruptions of the matching placebo for baricitinib. bTemporary interruption is defined as a temporary withholding of study drug that is followed by resumption of study drug during the study. MTX, methotrexate

The corrected Fig. 1 is given below.